Madopar (Benserazide, Levodopa)

Madopar, a combined levodopa and benserazide formulation, is used in the management of Parkinsonian disorders.

• Parkinson's disease (early stage): helps control initial motor symptoms such as tremor and rigidity.
• Parkinson's disease (advanced stage): reduces motor fluctuations and improves functional mobility.
• Parkinsonian syndrome: alleviates bradykinesia, rigidity and gait disturbances.

• Levodopa is absorbed from the gastrointestinal tract and crosses the blood‑brain barrier, where aromatic L‑amino acid decarboxylase converts it to dopamine. Benserazide, a peripheral DOPA decarboxylase inhibitor, does not cross the barrier and blocks the peripheral conversion of levodopa, thereby increasing the amount of levodopa that reaches the central nervous system and enhancing dopamine synthesis in the brain.

Madopar may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects

• Nausea: upset stomach often occurring after dose initiation.
• Vomiting: may accompany nausea in sensitive individuals.
• Orthostatic hypotension: dizziness upon standing due to blood pressure drop.
• Dizziness: general light‑headed feeling, especially when rising quickly.
• Insomnia: difficulty falling or staying asleep.
• Dyskinesia: involuntary movements with higher levodopa exposure.

Serious or Rare Side Effects

• Psychosis: hallucinations or delusional thoughts requiring medical attention.
• Severe hypotension: marked blood pressure fall leading to fainting.
• Cardiac arrhythmias: irregular heart rhythms that may be life‑threatening.
• Neuroleptic malignant syndrome: rare but critical reaction with fever and muscle rigidity.
• Anaphylaxis: acute allergic reaction with breathing difficulty and swelling.

Before prescribing Madopar, clinicians should consider several safety measures to minimize risks.

• Monitor blood pressure: watch for orthostatic hypotension, especially during dose titration.
• Assess hepatic function: adjust use in patients with significant liver impairment.
• Review psychiatric history: increased risk of hallucinations and confusion in susceptible individuals.
• Avoid abrupt discontinuation: sudden stop may precipitate worsening of Parkinsonian symptoms.
• Pregnancy and lactation: use only if potential benefit justifies potential risk to the fetus or infant.
• Store at ambient temperature: keep tablets in the original container, protect from moisture and light.

Madopar can interact with other medicines, altering its effectiveness or safety profile.

Major Interactions (Avoid)

• Non‑selective MAO inhibitors: may cause hypertensive crisis when combined.
• Antipsychotics (e.g., haloperidol): block dopamine receptors and reduce therapeutic benefit.
• High‑dose pyridoxine (vitamin B6): accelerates peripheral levodopa metabolism, decreasing central availability.

Moderate Interactions (Monitor Closely)

• COMT inhibitors (e.g., entacapone): increase levodopa plasma levels, requiring dose adjustment.
• Iron or calcium supplements: can reduce levodopa absorption if taken concurrently.
• Antihypertensive agents: additive blood pressure‑lowering effect may increase risk of hypotension.